IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
The Pharma Data
JUNE 18, 2021
I+V is the first all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination. The safety profile of I+V was generally consistent with the safety profile of the single agents and tolerability profiles were consistent with CLL treatment in the enrolled patient population. and 17.1%, respectively.
52 
Let's personalize your content